BNT162b2 mRNA Vaccine Effectiveness Given Confirmed Exposure: Analysis of Household Members of COVID-19 Patients.

Sivan GazitBarak MizrahiNir KalksteinAmi NeubergerAsaf PeretzMiri Mizrahi-ReuveniAmir Ben-TovTal Patalon

Published in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2021)

The BNT162b2 vaccine is effective in a high-risk real-life exposure scenario, but the protection rates afforded in these settings are lower than those previously described. Household members of patients infected with SARS-CoV-2 and individuals with a confirmed significant exposure to SARS-CoV-2 are still at risk of being infected even if fully vaccinated.

Keyphrases

sars cov
end stage renal disease
respiratory syndrome coronavirus
newly diagnosed
ejection fraction
chronic kidney disease
randomized controlled trial
systematic review
prognostic factors
coronavirus disease